VPPIPP and IPPVPP: Two Hexapeptides Innovated to Exert Antihypertensive Activity

• DOI: 10.1371/journal.pone.0062384
• Publication Date: 2013-05-02T01:17:33Z
• Authors: Fengyun Ding; Bingjun Qian; Xin Zhao; Shanqi Shen; Yun Deng; Danfeng Wang; Feng Zhang; Zhongquan Sui; Pu Jing
• Keywords: SERCA

In this study, two hexapeptides of IPPVPP and VPPIPP were innovated by using commercial antihypertensive peptides IPP VPP as domains cis-linked trans-linked, respectively. The chemically synthesized evaluated for the activity in vitro/vivo. vitro ACE-inhibitory study showed that (34.71±4.38%) has a significantly stronger than (13.17±0.25%) at treatment concentration 10 µmol/L, but it was weaker (56.97±2.40%) (P<0.05). However, VPPIPP, IPPVPP, lowered systolic blood pressure 21±0.9%, 17.4±1.3% 17.5±0.9%, respectively, rats 1.5 mg/kg body weight dosage. result consistent with mRNA level sarcoplasmic reticulum Ca2+, Mg2+ -ATPase Gene (SERCA 2a) rat hearts. Additionally, no negative impact on glycometabolism. results suggested could be potent bioactive functional foods people high pressure.